Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neogenix Oncology said that the researchers at Duke University Medical Center have received approval to move forward with a Phase I trial of the company’s lead therapeutic antibody, NPC-1C, in patients with advanced stage pancreatic or colorectal cancer.
Subscribe to our email newsletter
Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore – LIJ has also enrolled patients on this multi-center study.
NPC-1C is a novel, chimeric monoclonal antibody intended for the treatment of advanced pancreatic and colorectal cancer, and is the first of the Neogenix pipeline of antibodies that target specific cancers, the company said.
Pre-clinical studies have demonstrated that NPC-1C specifically targets pancreatic and colorectal cancer sparing healthy tissue.
Neogenix CEO Philip Arlen said that they look forward to fostering the relationships with both of these prestigious medical establishments for future Neogenix therapeutic development.